The development of education in rehabilitation medicine in China were analyzed and some solutions were suggested: increasing the investment in rehabilitation education; strengthening the teaching staff to improve the quality of teaching; establishing a standardized vocational system; intensifying the rehabilitation education for medical students.

The herpes simplex virus(HSV) Us3 gene encodes a ser/thr protein kinase(PK).As an accessory gene,it plays an important role in the regulation of the apoptosis of infected cells and virus release.Us3-induced alterations in the host cytomorphology are associated with enhanced intercellular virus spread,suggestive of a previously undescribed aspect of alphaherpesvirus spread.

Extranodal natural killer/T cell lymphoma (ENKTL) is an EBV-associated and highly aggressive subtype of non-Hodgkin lymphoma. Most patients are distributed in Asia and South America, and advanced-stage patients have poor prognosis. Reports on research progress of ENKTL in the 58th American Society of Hematology Annual Meeting covered multiple respects which range from basic research to clinical prognosis and treatment: further study on pathogenesis of ENKTL is developing based on high-throughput sequence, and new prognostic index system can help to stratify patients more exactly; what's more, novel regimens make more benefits to the clinical efficacy and safety of ENKTL patients.

Marginal zone lymphoma (MZL) accounts for approximately 10 % of non-Hodgkin lymphoma (NHL). It can be divided into three specific entities:extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), nodal marginal zone lymphoma (NMZL) and splenic marginal zone lymphoma (SMZL). MALT lymphoma is the most frequent overall, representing 7.5 % of all NHLs. Reports on research progress of MZL in the 58th American Society of Hematology Annual Meeting covered multiple respects which ranged from basic research to clinical prognosis and treatment. Based on the technology such as flow cytometry, cytogenetics and FISH, further study on pathogenesis of MZL is developing, and new prognostic index system can help to stratify patients more exactly and give a guidance to treatment. What's more, the change of therapy and new drugs will benefit to the clinical efficacy and safety of MZL patients.

Objective To investigate the function and possible action mechanisms of microRNA hsa-mir-634 in Vero cells.Methods The binding sites for hsa-mir-634 in the 3' UTR of cyclin D1 (CCND1) were predicated by bioinformatics methods.Then,the 3'UTR sequence of CCND1 containing the binding sites for hsamir-634 was amplified by PCR.Site-directed mutagenesis was used to create mutations in the binding sites.The wild and mutant 3' UTR sequences of the CCND1 gene were ligated into the psi-CHECK2 vector separately to construct dual-luciferase reporter vectors,including CHECK2-CCND1 wild,CHECK2-CCND1 mut 1,CHECK2-CCND1 mut 2 and CHECK2-CCND1 mut 3.Then,293T cells were transfected with the four constructed plasmids,and luciferase activity was measured 48 hours after the transfection.Vero cells were transfected with hsa-mir-634 mimics and negative control separately,and harvested after additional culture for different durations; the Vero cells remaining untreated served as the blank control.Subsequently,fluorescence-based quantitative PCR and Western blot were performed to detect the mRNA and protein expressions of CCND1 respectively in,3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,inner salt (MTS) assay to evaluate the proliferation of,and flow cytometry to detect the apoptosis in,Vero cells.Results The binding sites for hsa-mir-634 in the 3'UTR of CCND1 were successfully predicated.Sequencing results showed the successful construction of dual-luciferase reporter vectors.As the luciferase assay revealed,the overexpression of hsa-mir-634 could significantly inhibit the CCND1 3'UTR-mediated luciferase activity.Compared with the negative control,the hsamir-634 mimics markedly decreased the protein expression of CCND1,but had no obvious effect on the mRNA expression of CCND1 in Vero cells.The proliferation of Vero cells transfected with hsa-mir-634 mimics was significantly restrained compared with those transfected with the negative control,and the strongest restraining effect was observed on day 4 after the transfection.In addition,the overexpression of hsa-mir-634 also induced the apoptosis of Vero cells,with the apoptosis rate being 8.03％,7.96％ and 17.33％ in the blank control group,negative control group and mimics group respectively.Conclusion Hsa-mir-634 may regulate the proliferation and apoptosis of Vero cells via influencing the expression of CCND1.

Peripheral T-cell lymphoma (PTCL) is a relatively common subtype of non-Hodgkin lymphoma in China. PTCL is clinically highly aggressive, and it progresses rapidly. The current treatment methods are ineffective and the overall prognosis is poor. The 62nd American Society of Hematology Annual Meeting reported on the progress of PTCL molecular targeted therapy and immunotherapy, including programmed death receptor 1/programmed death receptor ligand 1 antibodies, JAK inhibitors, brentuximab vedotin, etc. These novel drugs bring a better prospect for patients.

Chronic lymphocytic leukemia (CLL) is an oncologic disease with clonal proliferation of lymphocytes. In recent years, great advances have been made in the basic and clinical research of CLL. The 62nd American Society of Hematology Annual Meeting in 2020 presented a detailed report on the latest advance in basic research on these diseases, providing a deeper understanding of how CLL occurs and develops, and playing a guidance role in the clinical treatment.

Objective To study the dynamic imaging changes of the uterine leiomyomas before and after uterine arterial embolization (UAE) treatment and to discuss its therapeutic mechanism. Methods Color Doppler senography and both plain and enhanced MR[scanning were performed in 45 patients with uterine leiomyomas before and after UAE. Plain CT scan was performed in all patients after UAE. All the patients were followed up for 3-16 months (average 10±3.5 months). Results In 41 of the total 45 cases, the color Doppler senography showed rich blood flow signals in leiomyomas and myometrium before UAE and no or less blood flow signals in both leiomyomas and myometrium on the first day after UAE. On the seventh day, the blood flow signal was still absent in leiomyomas while it was restored in myometrium, and the same phenomena remained in the first, the third and the twelfth month after UAE. In the other four eases, color Doppler sonography demonstrated blood flow signals inside leiomyomas on the seventh day after UAE and it remained till twelve months after embolization. The embolic agent (Lipiodol) was found in both leiomyomas and myometrium on CT scan for 45 cases on the first day of UAE. CT scan also showed the deposit of the Lipiodol in myometrium, but Lipiodol gradually vanished in leiomyomas at one, three and the twelve months after UAE. The enhancement was apparent in leiomyomas and myometrium on MRI scan in all 45 cases before UAE. The enhancement was found in the myometrium, but not in leiomyomas, on MRI scan in 39 cases 3 months after UAE. The other six cases demonstrated different degrees of enhancement in leinmyomas after embolization. In two cases the detachment of the leiomyomas were observed after embolization and the desquamating materials were pathologicallyproved to be necrotic tissue. The difference in the measuring data about leiomyoma volume between MPI and color Doppler sonography was of no statistical significance (P > 0.05). Conclusion The therapeutic mechanism of UAE for uterine leiomyomas is selectively embolizing the vascular bed of uterus, leading to subsequent necrosis of leiomyomas. The color Doppler sonography should be the fast choice for the dynamic imaging follow-up after UAE.

Peripheral T-cell lymphoma (PTCL) is a group of highly heterogeneous and aggressive non-Hodgkin's lymphoma with poor prognosis under current treatment algorithm.Reports on treatment of PTCL in the 56th American Society of Hematology (ASH) annual meeting cover comprehensive aspects,among which exploration of effective low-toxicity treatment strategies for patients with PTCL is coming into the focus of this meeting.THP-COP regimen,romidepsin,bortezomib alone or in combination with panobinostat,brentuximab vedotin and stem cell transplantation provide more attractive options for both untreated and refractory/relapsed patients with PTCL,while novel drugs including Duvelisib (IPI-145),crizotinib and antiPD-1 antibody offer new hope for patients with PTCL.

Peripheral T-cell lymphoma (PTCL) accounting for 10 % to 15 % of non-Hodgkin lymphoma (NHL) is characterized highly heterogeneous and aggressive clinical course. PTCL patients are prone to suffer from chemotherapy refractory and disease progression. Reports on research progress of PTCL in the 57th American Society of Hematology annual meeting covered multiple respects of PTCL. In basic research, the novel partner genes further improve the pathogenesis mechanism of ALK+anaplastic large cell lymphoma (ALCL). For prognostic indicators, GATA-3 expression detected by immunochemical assay provide a novel tool to monitor PTCL prognosis. Belinostat-CHOP, brentuximab vedotin-CHP, romidepsin-ICE regimens and stem cell transplantation provide more options for patients with PTCL, and the novel drugs such as alisertib, darinaparsin and denileukin diftitox offer new hope for PTCL patients in preclinical trials.